MentallyHealth.Org

Omni Bio receives U.S patent for treatment of viral infections

July 20, 2017

The New Patent will allow Omni Bio to develop treatments using the new peptides without a requirement to obtain additional licenses from third parties. In addition, these new peptides could qualify for the proposed FDA approval pathway for Biosimilar and Interchangeable Biological Products. This proposed process is expected to shorten the time needed for FDA approval if Omni Bio management decides to pursue the use of the new peptides in clinical studies for HIV-1 treatment.

Omni Bio's licensed technology portfolio also includes another issued patent related to HIV-1 treatment, U.S. Patent No. 6,849,605 that is in the same patent family as the New Patent and was issued on February 1, 2005. Although both of these patents concern HIV-1 treatment, the coverage related to U.S. Patent No. 6,849,605 is for new uses for known agents, and does not cover the peptides reported in the New Patent.

SOURCE Omni Bio Pharmaceutical, Inc.